Growth accelerates as AI demand broadens across the portfolio
- Life Sciences revenue bounced back to 9 percent organic growth in the third quarter.
- Diagnostics operating margins eclipsed 30 percent when excluding the China business.
- Customers building AI validation tools are driving demand beyond high content screening into other instruments.
- Signals software revenue surged to upper teens growth, resolving earlier execution fears.
- Revvity expects to outline long term targets at its November 2026 Investor Day.
A cleaner story meets a new catalyst
Revvity is proving its turnaround plan. The company signed a definitive agreement to sell its China Immunodiagnostics business. This removes a policy heavy overhang and firms up an exit timeline for late 2027. Stripping this out leaves a company better positioned to grow, which is already showing up in the numbers.
Profitability fears from earlier in the year are fading entirely. The core Life Sciences segment returned to 9 percent organic growth in the third quarter, driven by a broad recovery in pharma and biotech end markets. The Diagnostics unit also shined. Excluding the China business, Diagnostics operating margins crossed 30 percent in the quarter.
A new structural growth driver is taking shape. Artificial intelligence generates biological hypotheses, but those ideas need real world validation. This creates a lab in the loop workflow that directly benefits Revvity. Demand for the company's instruments is now expanding beyond high content screening into detection and high throughput screening.
The bear case rests on timing and backlog execution. Some of the third quarter reagent strength was aided by the timing of bulk screening orders, which may flatter the underlying run rate. If the large instrument backlog normalizes, sustainable order velocities will be tested.
Tools, tests, and repeat use
Revvity makes money by selling instruments, reagents, consumables, software, and services. Instruments are the expensive lab machines. Reagents and consumables are the items customers use again and again in testing workflows.
The company serves two broad customer groups. Life Sciences sells into research and drug development. Diagnostics sells into clinical testing areas such as immunodiagnostics and reproductive health.
The model works best when Revvity becomes a permanent part of a customer lab. That creates repeat sales and high switching costs. It breaks when customers delay lab spending or when the company has to sell a lower margin product mix.
What Revvity sells
Life Sciences Solutions
This includes reagents, consumables, and instruments like the Opera Phenix OptIQ. AI validation tools have created a massive backlog here.
Software
Software helps labs manage data and workflows. It rebounded to upper teens growth recently, driven by Signals AI and new AI native tools.
Immunodiagnostics
This business sells tools and tests used in clinical diagnostics. The business excluding China continues to accelerate.
Reproductive Health
This standout segment of Diagnostics includes newborn screening and the new GSP T1D 3-Plex kit for early diabetes detection.
China Immunodiagnostics
Revvity signed a definitive agreement to sell this business by late 2027 to reduce exposure to Chinese policy pressure.
Two segments, almost even size
Segment mix reflects recent historical revenue where Life Sciences and Diagnostics are roughly split at 51 percent and 49 percent. The planned China Immunodiagnostics divestiture will alter this mix once closed.
What could go wrong
Bulk order timing flatters growth
Low impact · Medium oddsSome of the third quarter reagent strength was aided by the timing of bulk screening orders. This adds a benefit that may flatter the underlying run rate. The company must show that sequential reagent demand remains strong without these bulk benefits.
Instrument backlog normalization
Medium impact · Medium oddsInstrument growth is currently supported by executing on a large backlog of orders. Once this backlog normalizes, it raises questions about sustainable order velocities. Management must prove that new AI demand can replace the backlog consumption.
China divestiture execution
Medium impact · Low oddsA definitive agreement is signed, but the deal does not close until late 2027. Any regulatory delays or stranded costs could disrupt operations and limit the strategic benefit of the sale.
Goodwill impairment in Life Sciences Solutions
Medium impact · Low oddsThe Life Sciences Solutions unit has a massive $4.5 billion goodwill balance. While the recent growth rebound heavily reduces the near term probability of a charge, the fair value buffer remains narrow.
In one breath
What does Revvity do?
Revvity sells tools used in health science research and clinical testing. Its products include instruments, reagents, consumables, software, diagnostics tools, and services.
Why is Revvity selling its China Immunodiagnostics business?
The business faces heavy policy pressure in China. Revvity is selling it to focus capital on higher growth, higher return areas of health sciences.
Is Revvity growing again?
Yes. The core Life Sciences segment returned to 9 percent organic growth in the third quarter, while Signals software surged to upper teens growth.
What is the biggest risk for Revvity stock?
A key risk is whether recent growth was pulled forward by bulk orders or supported unsustainably by backlogs. The company needs to prove order velocity can remain high once backlogs clear.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Diagnostics & Research companies
Companies near Revvity, Inc. in Finn's Diagnostics & Research industry ranking.

